|
Name |
(1-Methylnonyl)cyclohexane
|
Molecular Formula | C16H32 | |
IUPAC Name* |
decan-2-ylcyclohexane
|
|
SMILES |
CCCCCCCCC(C)C1CCCCC1
|
|
InChI |
InChI=1S/C16H32/c1-3-4-5-6-7-9-12-15(2)16-13-10-8-11-14-16/h15-16H,3-14H2,1-2H3
|
|
InChIKey |
XMDXQLIFVIVRKI-UHFFFAOYSA-N
|
|
Synonyms |
decan-2-ylcyclohexane; Decane, 2-cyclohexyl-; (1-Methylnonyl)cyclohexane; DECANE2-CYCLOHEXYL-,2-CYCLOH; 13151-73-0; 2-Cyclohexyldecane; Cyclohexane, 1-methylnonyl; (1-Methylnonyl)cyclohexane #
|
|
CAS | NA | |
PubChem CID | 524432 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 224.42 | ALogp: | 8.1 |
HBD: | 0 | HBA: | 0 |
Rotatable Bonds: | 8 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 0.0 | Aromatic Rings: | 1 |
Heavy Atoms: | 16 | QED Weighted: | 0.442 |
Caco-2 Permeability: | -4.679 | MDCK Permeability: | 0.00000994 |
Pgp-inhibitor: | 0.002 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.002 | 20% Bioavailability (F20%): | 0.3 |
30% Bioavailability (F30%): | 0.988 |
Blood-Brain-Barrier Penetration (BBB): | 0.142 | Plasma Protein Binding (PPB): | 98.17% |
Volume Distribution (VD): | 3.449 | Fu: | 1.41% |
CYP1A2-inhibitor: | 0.228 | CYP1A2-substrate: | 0.267 |
CYP2C19-inhibitor: | 0.351 | CYP2C19-substrate: | 0.178 |
CYP2C9-inhibitor: | 0.169 | CYP2C9-substrate: | 0.857 |
CYP2D6-inhibitor: | 0.329 | CYP2D6-substrate: | 0.083 |
CYP3A4-inhibitor: | 0.373 | CYP3A4-substrate: | 0.139 |
Clearance (CL): | 5.517 | Half-life (T1/2): | 0.047 |
hERG Blockers: | 0.163 | Human Hepatotoxicity (H-HT): | 0.039 |
Drug-inuced Liver Injury (DILI): | 0.647 | AMES Toxicity: | 0.008 |
Rat Oral Acute Toxicity: | 0.031 | Maximum Recommended Daily Dose: | 0.021 |
Skin Sensitization: | 0.942 | Carcinogencity: | 0.037 |
Eye Corrosion: | 0.991 | Eye Irritation: | 0.978 |
Respiratory Toxicity: | 0.245 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001039 | 0.605 | D03DVJ | 0.328 | ||||
ENC000545 | 0.506 | D0XN8C | 0.313 | ||||
ENC000558 | 0.463 | D03ZJE | 0.296 | ||||
ENC001162 | 0.455 | D05ATI | 0.274 | ||||
ENC000490 | 0.439 | D0I4DQ | 0.264 | ||||
ENC001155 | 0.439 | D02AXG | 0.261 | ||||
ENC002416 | 0.439 | D0G2KD | 0.256 | ||||
ENC001237 | 0.439 | D0IX1A | 0.250 | ||||
ENC001390 | 0.438 | D0Z5SM | 0.250 | ||||
ENC000797 | 0.434 | D0OK5I | 0.247 |